Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.SSE: 603707

Announcement on Progress in Repurchasing Shares

May 7, 2026 · Issued by Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · May 7, 2026

On 6ix: 6ix.com/news/announcement-on-progress-in-repurchasing-shares-99

Announcement on Progress in Repurchasing Shares

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. on 6ix

Earlier from Nanjing King-friend Biochemical Pharmaceutical

Announcement on Convening Performance and Cash Dividend Meeting for 2025 and Q1 2026May 6
Announcement on Proposing of Purchasing Liability Insurance for the Company and Directors, and Senior Management MembersApr 30
Announcement on Maturity and Redemption of "KING-FRIEND Convertible Bonds" and DelistingApr 15
Announcement on the Conversion Results and Stock Changes of ""Jianyou Convertible Bonds"Apr 2
The 3rd Indicative Announcement on Maturity and Redemption of "King-Friend Convertible Bonds" and DelistingMar 24

Later from Nanjing King-friend Biochemical Pharmaceutical

Announcement on Implementation Result of Shares Repurchase and Share ChangesMay 12
Announcement on Resolutions of the 1st Meeting of the 6th Board of DirectorsMay 21
Announcement on Implementation of Dividend Distribution for 2025Jun 3
Announcement on the Subsidiary's Receipt of the U.S. FDA Approval for the Manufacturing Site Transfer Registration of Desmopressin Acetate InjectionJul 4
Announcement on Obtaining the Drug Registration Approval for Propofol Emulsion Injection by the National Medical Products AdministrationJul 7

All Nanjing King-friend Biochemical Pharmaceutical news releases

Follow Nanjing King-friend Biochemical Pharmaceutical into a list and get an email when it puts out news.

Follow Nanjing King-friend Biochemical Pharmaceutical